Christopher Benecchi's most recent trade in Sage Therapeutics Inc was a trade of 3,255 Common Stock done . Disclosure was reported to the exchange on April 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc | Christopher Benecchi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 3,255 | 47,170 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 2,712 | 49,089 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.91 per share. | 10 Apr 2025 | 793 | 46,377 (0%) | 0% | 6.9 | 5,480 | Common Stock |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.91 per share. | 10 Apr 2025 | 661 | 48,428 (0%) | 0% | 6.9 | 4,568 | Common Stock |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.18 per share. | 13 Feb 2025 | 822 | 43,915 (0%) | 0% | 7.2 | 5,902 | Common Stock |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 40,000 | 40,000 | - | - | Stock Options (Right to buy) | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 20,000 | 44,737 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to buy) | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2024 | 6,250 | 24,737 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 16,200 | 23,242 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.96 per share. | 05 Aug 2024 | 4,755 | 18,487 (0%) | 0% | 9.0 | 42,605 | Common Stock |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 27,000 | 27,000 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 13,500 | 19,430 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 6,750 | 7,379 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.16 per share. | 03 Feb 2023 | 2,119 | 5,260 (0%) | 0% | 44.2 | 93,575 | Common Stock |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,500 | 9,500 | - | - | Stock Options (Right to buy) | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 11,400 | 11,400 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Christopher Benecchi | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) |